ASPI ASP Isotopes Inc.
Miscellaneous Chemical Products · Nasdaq · SEC CIK 1921865 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY552.4%
TTM net income YoY-28.0%
TTM EPS YoY0.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin19.4%
Operating margin-400.9%
Net margin-435.3%
FCF margin-322.6%
EBITDA margin-382.6%
Returns
ROE-63.9%
ROA-35.4%
ROIC (approx.)-107.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets33.2%
Debt / equity0.15x
Current ratio3.44x
Interest coverage-17.04x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-13.4%
Payout ratio—
Capex / revenue51.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $23.85M | $4.14M |
| Cost of revenue | $20.44M | $2.54M |
| Gross profit | $3.40M | $1.60M |
| R&D expense | $12.36M | $3.14M |
| SG&A expense | $48.24M | $24.81M |
| Operating income | -$59.91M | -$26.35M |
| Interest expense | $575,000 | $259,000 |
| Pretax income | -$159.56M | -$32.31M |
| Income tax | $282,000 | $111,000 |
| Net income | -$159.84M | -$32.42M |
| EBITDA | -$58.00M | -$25.88M |
| EPS (basic) | -2.11 | -0.63 |
| EPS (diluted) | -2.11 | -0.63 |
| Weighted avg. shares (diluted) | 83.01M | 55.67M |
| Balance sheet | ||
| Cash & equivalents | $279.57M | $61.89M |
| Short-term investments | $47.74M | $0 |
| Inventory | $1.10M | $66,000 |
| Current assets | $399.92M | $65.74M |
| PP&E, net | $33.29M | $22.35M |
| Goodwill | $5.18M | $3.17M |
| Intangibles | $675,000 | — |
| Total assets | $498.02M | $94.35M |
| Current liabilities | $32.70M | $7.06M |
| Short-term debt | $584,000 | $939,000 |
| Long-term debt | $1.47M | $1.44M |
| Total debt | $2.06M | $2.38M |
| Total liabilities | $235.12M | $43.18M |
| Shareholders' equity | $204.15M | $47.90M |
| Net debt | -$277.52M | -$59.51M |
| Shares outstanding | 111.68M | 72.07M |
| Cash flow statement | ||
| Operating cash flow | -$37.78M | -$16.70M |
| Capital expenditure | $9.65M | $9.68M |
| Free cash flow | -$47.43M | -$26.37M |
| Investing cash flow | -$110.79M | -$11.37M |
| Financing cash flow | $371.60M | $82.53M |
| Depreciation & amortization | $1.91M | $471,000 |
| Stock-based compensation | $16.02M | $8.56M |
| Dividends paid | $0 | $2.78M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.